Search ACRS
Aclaris Therapeutics, Inc.
Nasdaq · CIK 1557746
Last close4.39
Daily change-0.02 (-0.45%)
10 Years gain-82.78%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ACRS · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
45.2Momentum
0.0Acceleration
0.0Confidence
82.0Annual Revenue9
Quarterly Revenue31
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality20.3 / 25
Capital Efficiency7.5 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators2.4 / 5
Signals
Gross margin expansionGross margin improved by 4.5007 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 391.9746 percentage points.
Heavy share dilution · HIGHDiluted share count increased 16.6243%.
ROIC declining · MEDIUMROIC declined by 48.9366 percentage points.
Key Metrics
Revenue Growth TTM-20.65%OK
Revenue CAGR 3Y-35.93%OK
Gross Margin80.85%OK
Operating Margin-942.27%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-126.83%OK
Incremental Operating Margin 3Y-169.2%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y16.62%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $7.83M | $5.74M | -$76.38M | -$47.11M | -$47.22M | 73.28% | -975.91% | -603.42% | -222.27% | 122.56M |
| 2025 FY Dec 31, 2024 | $18.72M | $15.93M | -$141.93M | -$20.08M | -$20.20M | 85.09% | -758.18% | -107.88% | -280.2% | 77.3M |
| 2024 FY Dec 31, 2023 | $31.25M | $27.83M | -$97.36M | -$78.33M | -$79.63M | 89.05% | -311.55% | -254.84% | -848.78% | 69.81M |
| 2023 FY Dec 31, 2022 | $29.75M | $25.73M | -$89.85M | -$67.57M | -$68.17M | 86.48% | -302.01% | -229.13% | n/a | 65.21M |
| 2023 FY Dec 31, 2021 | $6.76M | $2.05M | -$89.72M | -$52.13M | -$52.44M | 30.29% | -1,327.07% | -775.65% | -143,194.28% | 56.73M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $8.70M | sum latest 4 fiscal quarters Revenue | OK | 0001104659-26-092065, 0001104659-25-107788 |
| Revenue Growth TTM | -20.65% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001104659-26-092065, 0001104659-25-107788 |
| Revenue CAGR 3Y | -35.93% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-020540 |
| Revenue CAGR 5Y | 3.84% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001104659-26-020540 |
| Gross Profit CAGR 3Y | -39.37% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-020540 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001104659-26-092065, 0001104659-25-107788 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 80.85% | Gross Profit / Revenue | OK | 0001104659-26-092065, 0001104659-25-107788 |
| Operating Margin | -942.27% | Operating Income / Revenue | OK | 0001104659-26-092065, 0001104659-25-107788 |
| ROIC | -126.83% | NOPAT / Average Invested Capital | OK | 0001104659-26-092065, 0001104659-25-107788 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001104659-26-092065 |
| Current Ratio | 3.46x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.06 | Revenue / Diluted Shares | OK | 0001104659-26-092065, 0001104659-25-107788 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |